Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 81Carcinoma, Non-Small-Cell Lung 76Neoplasms 71Ovarian Neoplasms 68Neoplasm Metastasis 30Fallopian Tube Neoplasms 30Carcinoma, Ovarian Epithelial 29Lung Neoplasms 26Unspecified Adult Solid Tumor, Protocol Specific 24Triple Negative Breast Neoplasms 20Endometrial Neoplasms 20Esophageal Neoplasms 18Stomach Neoplasms 16Colorectal Neoplasms 14Squamous Cell Carcinoma of Head and Neck 13Head and Neck Neoplasms 13Solid Tumors 12Small Cell Lung Carcinoma 10Melanoma 10Pancreatic Neoplasms 9Uterine Cervical Neoplasms 8Prostatic Neoplasms 8Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma 8Carcinoma, Renal Cell 8Carcinoma 8Brenner Tumor 8Urinary Bladder Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7

Interventions

LY3295668 erbumine 3Topotecan 1TAS-119 1Paclitaxel 1Midazolam 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Epilepsy × Paclitaxel × Clear all
NCT02134067 2024-09-05

Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1 Terminated
30 enrolled

Epilepsy, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡